Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

Krystal Biotech is engaged in developing genetic medicines. The biotech stock is near a buy point with earnings due soon.

Cory has been a professional trader for two decades. In addition to trading and investing he's widely published and coaches individual clients on the finer points of gaining an edge in the market.

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...